We are live on ! Find out more

Codexis

CDXS

Market cap $159M

1.45 USD

-0.03

2.03%

At close Updated Sep 15, 11:14 AM EDT

1 day

-2.03%

5 days

1.4%

1 month

-8.81%

3 months

-41.77%

6 months

-3.33%

Year to date

-9.94%

1 year

-40.57%

5 years

-94.14%

10 years

-65.14%

About: Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Employees: 146

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 63.6%

Negative 9.1%

Codexis to Participate in Cantor Global Healthcare Conference 2026

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.

Codexis to Participate in Cantor Global Healthcare Conference 2026

Zacks Investment Research

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript

Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript

Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis Q2 Earnings Call Highlights

Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.

Codexis Q2 Earnings Call Highlights

Codexis Reports Second Quarter 2026 Financial Results

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.

Codexis Reports Second Quarter 2026 Financial Results

Codexis Appoints David Butler, PhD, to Strategic Advisory Board

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the appointment of David Butler, PhD, to its Strategic Advisory Board (SAB).

Codexis Appoints David Butler, PhD, to Strategic Advisory Board

Codexis to Report Second Quarter 2026 Financial Results on August 11

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2026 on Tuesday, August 11, 2026, following the close of market.

Codexis to Report Second Quarter 2026 Financial Results on August 11

Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)

CDXS is now shifting toward differentiated enzymes and ECO Synthesis, which I think could pay off as commoditized small molecules become less attractive. We've now seen a customer manufacturing order, as well as CDMO evaluations that validate there's interest in CDXS's offerings. However, I concede that this bull case remains inherently speculative until we see recurring commercial demand or larger contracts.

Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)

Codexis Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $1.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $23.1 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions. Codexis has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 2,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Codexis Announces Pricing of Public Offering of Common Stock

See News Rankings

Price charts implemented using Lightweight Charts™